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developed from the perspective of a Belgian hospital. Costs are discounted at 3%, in
line with Belgian guidelines for pharmacoeconomic evaluation. The model takes
into account device acquisition costs and other direct and indirect costs associated
with NSIs occurring from infusion, injection, blood collection and insulin admin-
istration for diabetes care. Model input data were derived from the Institut National
d’Assurance Maladie-Invalidité (INAMI), published studies, clinical guidelines, and
market research. RESULTS: For a 420 bed hospital, an estimated 384,720 sharps
procedures occur annually. Over five years, the total cost of conducting these pro-
cedures using conventional devices was estimated to be €580,700, of which
€326,700 or 56% was spent managing 310 NSIs. If all procedures were instead con-
ducted using SEDs, the model estimates that the number of NSIs would be reduced
to 75. Total costs with SEDs are estimated to be €528,500, representing an overall
cost saving of €52,200 or 9%. Greater acquisition costs for SEDs are offset by a
decline in NSI management costs. CONCLUSIONS: Costs associated with NSIs are a
significant avoidable cost of conducting sharps procedures. SEDs may reduce the
economic burden of managing NSIs, which may partially or completely offset any
increase in device acquisition costs.
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OBJECTIVES: Coronary angiography is the current gold standard in diagnosing
coronary lesions. However, coronary angiography does not definitively determine
whether a lesion is ischemic or not. Compared to angiography alone, Fractional
Flow Reserve (FFR) has demonstrated clinical superiority in diagnosing cardiac
lesion functional severity, while concurrently providing cost savings. The goal of
this model is to demonstrate the hospital budgetary implications of utilizing FFR to
guide clinical decision making in PCIs compared to angiography alone. METHODS:
A customizable Excel®-based hospital budget impact model was developed for a
hypothetical cohort of 500 patients with multivessel coronary disease. Cost com-
ponents included procedural, device, hospital stay and cardiovascular complica-
tion costs during the one-year period after PCI. A decision tree model was utilized
to convert the expected probabilities of cardiovascular complications into expected
costs. Probabilities and costs were derived from The Fractional Flow Reserve versus
Angiography for Multivessel Evaluation (FAME) clinical trial data. Costs were con-
verted to 2011 US dollars. Sensitivity analysis was carried out over reported ranges
of values of model inputs. RESULTS: Using Fractional Flow Reserve in 20% of the
multivessel cases resulted in estimated cost savings of $297,247 per year compared
to using angiography alone in all of the multivessel cases. Fractional Flow Reserve
usage resulted in reduced costs of the procedure, hospital stay and complications.
Potential cost savings were most sensitive to variations in the cost of hospitaliza-
tion and the probabilities of cardiovascular complications. CONCLUSIONS: Analy-
sis shows that compared to angiography alone, FFR-guided coronary intervention
for patients with multivessel disease both (1) reduces rates of adverse events and
(2) reduces total costs including procedural, hospital and complication costs. As
such, FFR provides hospitals a cost saving technology with superior clinical out-
comes as compared to angiography alone
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OBJECTIVES: Care for cardiovascular diseases is an important issue for health care
systems. Coronary artery bypass grafting surgery (CABG) is utilized to treat coro-
nary artery disease. Intensive care stay (ICS) and acute stroke (AS) are important
drivers of post-operative costs. In Turkey, ICS and AS receive add-on payments to
the packaged payment for CABG from the Social Security Agency (SGK). Effective
use of regional cerebral oxygen saturation monitoring (rSO2) during CABG reduces
intensive care stay (ICS) from 1,87 to 1,25 days and acute stroke (AS) incidence from
2,21% to 0,61%. We modelled the potential impact of SGK add-on payment for rSO2
on SGK add-on payments for ICS and AS after CABG.METHODS: Turkish volume of
CABG was estimated as 47.973 procedures for 2012 (Covidien ICD-10 study of Tur-
key), increasing at 7,2% per year (National Cardiology Policy Report). SGK was as-
sumed to cover 75% of procedures. ICS cost was taken from SGK. AS cost was taken
from published data. Add-on payment for rSO2 was taken as 400TL per patient (cost
of Covidien INVOS™ disposable sensor). Utilization of rSO2 in CABG with add-on
payment was estimated as 15% in 2013, 30% in 2014, and 50% in 2015. Discount rate
was 5%. RESULTS: Under current care paradigms, estimated SGK cost for ICS and
AS following CABG will be 82,9, 84,5 and 86,0 million TL in 2013, 2014 and 2015, respec-
tively. However, if add-on payment facilitates utilization and benefits of rSO2 in CABG,
potential SGK cost for ICS and AS following CABG would decrease to 78,5, 75,3 and 70,6
million TL in those years. CONCLUSIONS: The cost of ICS and AS after CABG is
substantial in Turkey. Add-on payment for rSO2 during CABG may decrease cumu-
lative ICS and AS costs by approximately 29 million TL between 2013 and 2015.
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OBJECTIVES: Recent literature suggests complication rates associated with current
Vascular Closure Devices (VCDs) are comparable or reduced when compared to
manual compression. However, well-documented differences exist among VCDs
regarding the type and frequency of complications. A recent global budget impact
model based on a naïve indirect treatment comparison (ITC) estimated the cost-
savings associated with use of the VCD EXOSEAL™ vs. Angioseal™, Starclose™,
Perclose™ and Mynx™ from the US hospital perspective. Based on this ITC, the
analysis was adapted to Italy and Spain from the National Health System (NHS)
perspective over a 1 year time horizon. METHODS: The ITC was used to calculate
the incidence of reinterventions (i.e. amputation (AM), vascular surgery (VS), en-
dovascular procedure (EP), transfusion (TR) and ultrasound guided interventions
(UGI)) following complications associated with each VCD. The annual number of
VCDs used and costs of reinterventions were obtained from local databases. The
means and 95% confidence intervals (95%-CI) for the budget impact were estimated
using bootstrap methods (1.000 simulations) assuming 100% use of ExosealTM vs.
100% use of another VCD, and 100% use of Exoseal vs. 2010 VCD market-share for
percutaneous coronary interventions (PCI) procedures. Device acquisition costs
were assumed identical. RESULTS: Savings per procedure with EXOSEAL™ (Italy/
Spain) would be approximately of (22,8€/11,9€) vs. Angioseal™, (15,5€/13,5€) vs.
Starclose™, (83,1€/72,6€) vs. Perclose™ and (11,2€/16,4€) vs. Mynx™. Considering
90.239 and 37.064 annual PCI procedures with VCDs in Italy and Spain respectively
(1 VCD per procedure), 100% use of EXOSEAL™ vs. combined use of VCDs could save
2.680.870€ (95%-CI: 2.538.334€ – 2.823.405€) for the Italian NHS and 797.070€ (95%-CI:
734.231€ – 859.909€) for the Spanish NHS. CONCLUSIONS: This analysis suggests
use of EXOSEAL™ in patients undergoing PCI procedures may result in important
cost-savings for the Italian and the Spanish NHS. Additional data will be required to
confirm low complication rates with EXOSEAL™.
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OBJECTIVES: There has been growing interest in the potential benefits arising from
the use of medical diagnostic technologies, primarily due to possible reductions in
resource use and time to diagnosis. The objective of this study was to provide an
estimate of the potential financial implications resulting from the introduction of
Simtomax®, a rapid point of care test, for the diagnosis of coeliac disease and IgA
deficiency. The study, performed from the perspective of the UK NHS, aimed to
demonstrate that the additional test acquisition costs would be offset by resource
savings. METHODS: A 1 year budget impact model was developed looking at the
key financial drivers of diagnosing coeliac disease, based on the NICE pathway.
This included the cost of blood tests and other contributing costs, including GP
visits, nurse visits, paediatric outpatient visits for testing children and carriage.
The model compares Simtomax® to the current diagnosis pathway which com-
prises of serological testing for IgA tissue transglutaminase (tTGA) and a possible
IgA deficiency test, using ELISA laboratory testing. Costs were taken from national
sources with the exception of carriage costs which were estimated by a clinician as
a national source was not available. RESULTS: Although the cost of acquiring Sim-
tomax® was £22.51 greater than the cost of a tTGA test, an overall cost saving of
approximately £40.14 per patient was achieved as a result of resource savings. The
analysis estimated that the introduction of Simtomax® could result in cost savings
of up to £5,932,885 per annum to the UK NHS. CONCLUSIONS: The analysis sug-
gests that the use of Simtomax® for the diagnosis of coeliac disease would be
financially beneficial because it may result in decreased resource use and cost
savings. Additionally, the time required for health care professionals to diagnose
coeliac disease could be reduced meaning patients receive treatment faster.
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OBJECTIVES: The STERRAD® Sterilizers are a versatile group of systems that use
low-temperature, hydrogen peroxide gas plasma technology to sterilize medical
devices safely and effectively. Literature data suggest significant reductions in the
number of damaged rigid endoscopes with STERRAD® compared to steam steril-
ization. The aim of this study was to assess the potential savings associated with
the STERRAD®100NX™ system compared to steam for endoscope sterilization.
METHODS: A dynamic budget-impact model was developed to estimate the costs
with the use of the STERRAD® 100NX™ system compared to steam, from a hospital
decision-maker perspective and with a one-year time-horizon. Data were collected
from two Italian hospitals running approximately 800 sterilization cycles per year,
and costs of sterilization per cycle, endoscope repair costs, testing and mainte-
nance costs were considered. A conservative estimate for the endoscope repair
cost reduction of 33% was used in the base case analysis. Gamma distributions for
cost parameters and Bootstrap methods were used to generate 1000 simulations.
The acquisition costs of STERRAD® 100NX™ and steam systems were not
considered. RESULTS: In the base case analysis, the annual costs with STERRAD®
were €55,540, and the mean costs (SD) from the simulations were €51,471 (€25,186).
For steam sterilization, the corresponding figures were annual costs of €59,736 for
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the base case, resulting in a cost-saving with STERRAD® of €4,196, and a mean cost
of €58,078 (SD €33,785) from the simulations, giving mean probabilistic cost-savings
with STERRAD® of €6,608. With a reduction in endoscope repair costs of 41.6%, as
calculated from published studies, savings with STERRAD®increased to €8,803.
CONCLUSIONS: This analysis suggests that the use of STERRAD® for the steriliza-
tion of endoscopes may result in important cost-savings compared to reprocessing
with steam. Costs for the sterilization of other reusable heat-sensitive devices were
not considered; therefore these cost-savings may have been underestimated.
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OBJECTIVES: A major goal in the work-up of women with pelvic mass is to assess
the risk of ovarian malignancy. Ovarian cancer has high mortality rates with 3000
deaths annually in Veneto Region of Italy. The utility of novel biomarkers, such as
HE4 (Human Epididymis Protein 4), in diagnosis of ovarian cancer was investigated
by a number of groups. These studies showed a high negative predictive value
(NPV) of 97-99% indicating that almost all patients who tested negative were cor-
rectly diagnosed as having benign ovarian pathology. The objective of our study
was to perform a budget impact analysis (BIA) and estimate the annual cost of the
introduction of HE4 testing for differential diagnosis of women with pelvic mass for
Regional Health Service in Veneto. METHODS: The study compares the cost of
surgical intervention for pelvic mass versus the preoperative laboratory testing of
HE4 biomarker for pelvic mass diagnosis. The incidence of pelvic masses, surgical
interventions and costs for both procedures (surgery and HE4 test) were based on
available statistics and reimbursement rates. RESULTS: AND CONCLUSIONS: If
HE4 testing was performed in all potentially eligible women who present for pre-
operative pelvic mass evaluation in Veneto Region at a proposed cost of €35/pa-
tient, the total cost for Regional Health Service would be €1.130.075. Given the low
false-positive rate for HE4 test, it can be hypothesised that cost from unnecessary
procedures would be reduced. The BIA showed that if HE4 testing was performed in
all potentially eligible women for preoperative pelvic mass evaluation (1st test) and
as an additional 2nd follow up test in women who tested negative and avoided
surgery, a conservative estimate of 10% reduction of surgical interventions would
have a cost-neutral or even slightly positive impact on annual budget in Veneto,
Italy.
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OBJECTIVES: Balloon sinuplasty (BSP) is a novel technology to treat patients with
chronic rhinosinusitis (CRS) refractory to conservative care. The BSP technology is
an alternative tool used during functional endoscopic sinus surgery (FESS). Recent
clinical trials have identified favorable clinical outcomes of BSP compared to classic
FESS. Specifically, the non-invasiveness of the procedure may result in fewer post-
operative treatments and complications. These findings point to potential cost
effectiveness of the BSP procedure versus classic FESS. In this study, the cost of
treatment for patients undergoing either classic FESS or BSP was compared using a
budget impact model. The model was designed to be versatile and allow for coun-
try-specific analyses using regional cost and care assumptions. METHODS: The
budget impact model was designed to identify costs by therapeutic treatment (FESS
vs. BSP vs. conservative care). Inputs included frequency and unit costs of preop-
erative work-ups (such as office visits and diagnostic procedures), index in- or
out-patient surgery, frequency and unit cost of treatment for post-operative com-
plications, post-operative procedures and relapse/reoperation rates. Secondary
analyses included productivity calculations using a human capital approach. The
follow-up period was limited to 2 years post-index. Supplementary analyses were
conducted to determine the cost impact of early intervention on total budget.
RESULTS: At 1 and 2-year post-operative time points and using assumptions spe-
cific to different European countries, the cost of BSP was lower in specific target
groups than that of FESS. CONCLUSIONS: The model suggests savings in target
groups, based on clinical outcomes data from BSP and classic FESS, at 2 years
post-operative. The patient friendly technology offers to payers the opportunity to
seek efficient resource utilization whilst diminishing costs.
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OBJECTIVES: To estimate the costs of drug-eluting balloons (DEB) as treatment for
intermittent claudication due to superficial femoral artery atherosclerosis by pay-
ors and providers in the U.S., compared to percutaneous transluminal angioplasty
(PTA), bare metal stents (BMS) and drug-eluting stents (DES). METHODS: We esti-
mated the costs of the index procedure (DEB, PTA, BMS, or DES) and clinically-
driven target lesion revascularization (TLRs). TLR proportions were pooled from
randomized controlled trials. Other follow-up durations were converted via rates
to six-month proportions. The distribution of secondary revascularization tech-
niques (given index procedure) were derived from expert opinion. U.S. Medicare
Ambulatory Payment Classification (APC) and Current Procedural Terminology
(CPT) payments constituted payors’ budget impact. APC revenue minus device
costs constituted the overhead revenue for providers. The time horizon was two
years for both scenarios. Second-order Monte Carlo-simulation varied clinical pa-
rameters in 5,000 random draws. RESULTS: Pooled TLR rates were comparable
between DEB, BMS, and DES (5.1%, 5.9%, and 4.8%, respectively) but not to POBA
(16.1%). Initial DEB was the least expensive strategy from a payor perspective
($6,715). From the provider perspective, BMS provided the most overhead revenue
after device costs ($8,250 vs. $4,614 for DEB). Probabilistic sensitivity analyses re-
vealed that 90-94% of simulations were cost-saving when comparing DEB with
POBA. CONCLUSIONS:While the clinical performance of DEB is comparable to BMS
and DES, DEB is a cost-saving strategy from a U.S. payor perspective. Clinical pref-
erences, which may vary from lesion to lesion, must be considered.
PMD21
COST COMPARISON OF SPINAL FUSION PROCEDURES WITH GRAFTON MIXED
WITH LOCAL BONE COMPARED TO ILIAC CREST BONE
Borgman B
Medtronic Trading Sàrl., Tolochenaz, Switzerland
OBJECTIVES: Clinical evidence suggest that Grafton, a demineralized bone matrix,
mixed with local bone (LB) can achieve similar fusion rates in lumbar fusion spinal
surgery as iliac crest bone graft (ICBG). It would thus be possible to avoid harvest
site morbidity. However, as of yet the cost difference between these alternatives
have not been investigated. The objective is to study the cost for spinal fusion
surgery with Grafton and LB mix compared with ICBG. METHODS: A modeling
approach was taken. Additional resource use for second harvest site required for
ICBG procedures were taken from published literature. U.K. costs were used and
collected from publicly available price lists and published HTA reports. One way
sensitivity analysis was performed. RESULTS: ICBG and a second surgery site due
to bone harvesting was found in the literature to be associated with pain, difficulty
walking and working, infections, hematomas, prolonged wound drainage, reopera-
tions, additional surgery time and hospital stay. Health care costs for these re-
sources were estimated to be £958 per patient. Total treatment cost for spinal
fusion with Grafton and LB compared with ICBG was £10821 compared with £11021.
Procedures using Grafton and LB mix were thus estimated to have lower costs of
£200. Grafton and LB was still cost saving when no costs for complications were
included in a one-way sensitivity analysis, and when other studies were used to
inform additional surgery time and hospital stay with ICBG. Of nine scenarios ICBG
was cost saving in one. CONCLUSIONS: In this study spinal fusion surgery with
Grafton and LB was found to generate similar or lower costs than comparable
procedures with ICBG. Given that previous studies have shown that the clinical
outcomes are comparable between the two interventions Grafton mixed with LB
can be considered a viable alternative to ICBG in spinal fusion procedures.
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OBJECTIVES: Estimate the short- and long-term financial impact of early referral
for ILR (REVEAL®) of Unexplained Syncope patients under the perspective of the
Portuguese National Health Service. METHODS: Markov Model to estimate the ex-
pected number of Hospital Admissions due to Unexplained Syncope and their
financial impact, comparing ILR vs. patients following conventional diagnostic
pathways, in a 3 year and lifetime time horizons. A hypothetical cohort of patients
with unexplained recurrent syncope, age61 years old with similar characteristics
to the patient population from the PICTURE trial was modeled. These patients face
annually the probability of death, receiving a diagnosis and suffering a recurrent
syncope event. Model parameters and transition probabilities were derived from
landmark publications. The average cost of a syncope admission was estimated
from the latest official Portuguese cost tables and the PICTURE trial. Costs were
discounted at 5% p.a. The cost of implanting ILRs was estimated for a total of 215
patients with unexplained syncope, based on the total number of hospitalised
syncope patients during one year in Portugal according to the latest National DRG
report. PSA was performed to explore the impact of the uncertainty in the input
parameters (HR of Death; number of syncope events per year and yield of diagnose)
in three year and lifetime time horizons. RESULTS: The average cost of an event
was estimated at 1.960€. The total cost of syncope admissions over three years was
66% lower with ILR (501.338€) vs. SoC (1.486.503€). ILR clearly lead to earlier diag-
nosis and consequently to a lower number of syncope admissions allowing impor-
tant savings, that in this case were estimated between 985.165€ over three years
and 2.177.254€ over patient lifetime. CONCLUSIONS: The utilization of Reveal®
leads to less hospital admissions and investigations, proving its potential for sig-
nificant cost savings in the Portuguese population.
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